All these phenotypic features clearly illustrate the biological disadvantage of APOE-4 homozygotes and the potential consequences that these patients may experience when they receive pharmacological treatment for AD and/or concomitant pathologies [2,3,4,6,112,113,114,115,116,117,118,119,120,121,122,123,124]. This evidence concerns the gene APOE and Alzheimer disease.